|
USA-MN-DULUTH Azienda Directories
|
Azienda News:
- Bavarian Nordic Annual Report 2024 - ml-eu. globenewswire. com
Strategic priorities 21 Travel Health 22 Public Preparedness 23 Innovation Corporate information 26 Shareholder information 28 Risk management Letter from the Chair and the CEO Our purpose and strategy Bavarian Nordic at a glance Partnering for global health Strong regulatory progress in 2024 Our first 30 years Raw materials
- Bavarian Nordic Publishes Annual Report 2024 - Inderes
Upon approval, Bavarian Nordic received a Priority Review Voucher, which the Company intends to monetize when appropriate In February, Bavarian Nordic entered a strategic partnership with Biological E Limited, initially signing a contract manufacturing agreement with the aim to provide capacity for the future supply of chikungunya vaccines to
- Bavarian Nordic
Bavarian Nordic Announces Interim Results for the First Three Months of 2025 May 06, 2025 Bavarian Nordic Awarded Contract Options from the U S Government for Production and Supply of Freeze-dried Smallpox Mpox Vaccines
- Bavarian Nordic Announces Interim Results for the First - GlobeNewswire
Exercised options total USD 143 6 millionSecures manufacturing and supply of freeze-dried JYNNEOS® to the U S in 2026 COPENHAGEN, Denmark, May 6, 2025 – Bavarian Nordic A S (OMX: BAVA
- Bavarian Nordic A S | Globenewswire - via. ritzau. dk
Paul Chaplin, President Chief Executive Officer of Bavarian Nordic said: “A very strong first quarter for our Travel Health business, demonstrating a 52% growth year-over-year and puts us ahead of our strategic goal of an average annual growth rate of 10-12% for this part of the business until 2027 We also recorded our first US sales of the chikungunya vaccine after its approval in
- FDA Approves Bavarian Nordic’s Chikungunya Vaccine or Those 12 and Older
The approval of Bavarian Nordic’s vaccine provides an additional tool in global efforts to combat the disease, which remains a public health concern in several regions References 1 Bavarian Nordic Bavarian Nordic receives U S FDA approval of chikungunya vaccine for persons aged 12 and older Bavarian Nordic A S Published February 14, 2025
- Bavarian Nordics Strategic Share Buy-Back: A Boost to Capital . . .
Bavarian Nordic A S, a global vaccine company, has announced a strategic share buy-back program valued at up to DKK 150 million, slated for early 2025 This move, driven by a robust financial position and the prospects of its Travel Health business, signals the company's confidence in its future and potential benefits for its capital structure
- Bavarian Nordic Partners with Biological E Limited to Expand Global . . .
COPENHAGEN, Denmark, February 25, 2025 – Bavarian Nordic A S (OMX: BAVA) today announced a strategic partnership with Biological E Limited (BE) to expand access to Bavarian Nordic’s
|
|